Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127221842 | 12722184 | 2 | F | 201311 | 20160913 | 20160907 | 20160916 | EXP | CA-PFIZER INC-2016420460 | PFIZER | 67.00 | YR | F | Y | 61.50000 | KG | 20160916 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127221842 | 12722184 | 1 | PS | REVATIO | SILDENAFIL CITRATE | 1 | ATTEMPT TO SWITCH TO ADCIRCA | D | 21845 | FILM-COATED TABLET | |||||||||
| 127221842 | 12722184 | 2 | SS | REVATIO | SILDENAFIL CITRATE | 1 | RE-STARTED | D | 21845 | FILM-COATED TABLET | |||||||||
| 127221842 | 12722184 | 3 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 100 MG, 2X/DAY | 0 | 100 | MG | BID | ||||||||
| 127221842 | 12722184 | 4 | C | WELLBUTRIN | BUPROPION HYDROCHLORIDE | 1 | 10 MG, 2X/DAY | 0 | 10 | MG | BID | ||||||||
| 127221842 | 12722184 | 5 | C | ALLOPURINOL. | ALLOPURINOL | 1 | 100 MG, DAILY | 0 | 100 | MG | |||||||||
| 127221842 | 12722184 | 6 | C | ATORVASTATIN | ATORVASTATIN | 1 | 20 MG, DAILY | 0 | 20 | MG | |||||||||
| 127221842 | 12722184 | 7 | C | METOLAZONE. | METOLAZONE | 1 | 2.5 MG, EVERY 3 DAYS | 0 | 2.5 | MG | |||||||||
| 127221842 | 12722184 | 8 | C | IRON | IRON | 1 | UNK | 0 | |||||||||||
| 127221842 | 12722184 | 9 | C | VITAMIN D /00107901/ | ERGOCALCIFEROL | 1 | Subcutaneous | UNK | 0 | ||||||||||
| 127221842 | 12722184 | 10 | C | MULTIVITAMIN /02160401/ | VITAMINS | 1 | UNK | 0 | |||||||||||
| 127221842 | 12722184 | 11 | C | TYLENOL | ACETAMINOPHEN | 1 | UNK | 0 | |||||||||||
| 127221842 | 12722184 | 12 | C | WARFARIN | WARFARIN | 1 | UNK | 0 | |||||||||||
| 127221842 | 12722184 | 13 | C | ADVAIR HFA | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | UNK | 0 | |||||||||||
| 127221842 | 12722184 | 14 | C | SENOKOT | SENNOSIDES | 1 | UNK | 0 | |||||||||||
| 127221842 | 12722184 | 15 | C | DIOVAN | VALSARTAN | 1 | 80 (UNITS NOT PROVIDED) | 0 | |||||||||||
| 127221842 | 12722184 | 16 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | 18 UG, UNK | 0 | 18 | UG | |||||||||
| 127221842 | 12722184 | 17 | C | CONJUGATED ESTROGENS | ESTROGENS, CONJUGATED | 1 | UNK | 0 | |||||||||||
| 127221842 | 12722184 | 18 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | UNK | 0 | |||||||||||
| 127221842 | 12722184 | 19 | C | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 127221842 | 12722184 | 20 | C | RABEPRAZOLE | RABEPRAZOLE | 1 | 0 | ||||||||||||
| 127221842 | 12722184 | 21 | C | APO-K | POTASSIUM CHLORIDE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127221842 | 12722184 | 1 | Pulmonary hypertension |
| 127221842 | 12722184 | 4 | Depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127221842 | 12722184 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127221842 | 12722184 | Disease progression | |
| 127221842 | 12722184 | Pulmonary hypertension |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127221842 | 12722184 | 1 | 201104 | 0 |